Skip to main content
SpringerLink
Log in

Novel Drug Delivery System for Age-related Macular Degeneration Using Nanotechnology

  • Published:
NanoBiotechnology

Abstract

Age-related macular degeneration (AMD) is a leading cause of legal blindness in developed countries. Even with the recent advent of several treatment options such as photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) therapy for the treatment of exudative AMD, characterized by choroidal neovascularization (CNV), their efficacy is still limited. Thus, in this review article, we investigated novel drug delivery system for AMD using nanotechnology. Polyion complex (PIC) micelle has a size range of several tens of nanometers formed through electrostatic interaction, and accumulates in solid tumors through enhanced permeability and retention (EPR) effect. The distribution of the PIC micelle encapsulating fluorescein isothiocyanate-labeled poly-l-lysine (FITC-P(Lys)) in experimental CNV in rats was investigated. PIC micelle accumulates in the CNV lesions and is retained in the lesion for as long as 168 h after intravenous administration. PIC micelles can be used for achieving effective drug delivery system to CNV. Although PDT is a main treatment option for CNV, most patients require repeated treatments. For effective PDT against AMD, the selective delivery of photosensitizer to the CNV lesions and an effective photochemical reaction at the CNV site are necessary. The characteristic dendritic structure of the photosensitizer prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. A supramolecular nanomedical device, i.e., a novel dendritic photosensitizer encapsulated by a polymeric micelle formulation was employed for an effective PDT for AMD. With its highly selective accumulation on CNV lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity. Our results will provide a basis for an effective approach to PDT for AMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Ferris FL 3rd, Fine SL, Hyman L. Arch Ophthalmol 1984;102:1640–2.

    Google Scholar 

  2. Bressler NM, Bressler SB, Fine SL. Surv Ophthalmol 1988;32:375–413.

    Article  CAS  Google Scholar 

  3. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1242–57.

    Google Scholar 

  4. Treatment of Age Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329–45.

    Google Scholar 

  5. The Eyetech Study Group. Ophthalmology 2003;110:979–86.

    Article  Google Scholar 

  6. Heier JS, Antoszyk AN, Pavan PR, et al. Ophthalmology 2006;113:633–42.

    Article  Google Scholar 

  7. Kimura H, Yasukawa T, Tabata Y, Ogura Y. Adv Drug Deliv Rev 2001;52:79–91.

    Article  CAS  Google Scholar 

  8. Kataoka K, Harada A, Nagasaki Y. Adv Drug Deliv Rev 2001;47:113–31.

    Article  CAS  Google Scholar 

  9. Kakizawa Y, Kataoka K. Adv Drug Deliv Rev 2002;54:203–22.

    Article  CAS  Google Scholar 

  10. Matsumura Y, Maeda H. Cancer Res 1986;46:6387–92.

    CAS  Google Scholar 

  11. Nakanishi T, Fukushima S, Okamoto K, et al. J Control Release 2001;74:295–302.

    Article  CAS  Google Scholar 

  12. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Pharm Res 2001;18:1035–41.

    Article  CAS  Google Scholar 

  13. Harada A, Kataoka K. Macromolecules 1995;28:5294–9.

    Article  CAS  Google Scholar 

  14. Yanagi Y, Tamaki Y, Obata R, Muranaka K, Homma N, Matsuoka H, Mano H. Invest Ophthalmol Vis Sci 2002;43:3495–9.

    Google Scholar 

  15. Yanagi Y, Tamaki Y, Inoue Y, Obata R, Muranaka K, Homma N. Invest Ophthalmol Vis Sci 2003;44:751–4.

    Article  Google Scholar 

  16. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, Ogura Y. Invest Ophthalmol Vis Sci 1999;40:2690–6.

    CAS  Google Scholar 

  17. Harada A, Kataoka K. J Control Release 2001;72:85–91.

    Article  CAS  Google Scholar 

  18. Harada–Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka K. Gene Ther 2002;9:407–14.

    Article  CAS  Google Scholar 

  19. Harada A, Togawa H, Kataoka K. Eur J Pharm Sci 2001;13:35–42.

    Article  CAS  Google Scholar 

  20. Ideta R, Yanagi Y, Tamaki Y, et al. FEBS Lett 2004;557:21–5.

    Article  CAS  Google Scholar 

  21. Meads C, Hyde C. Br J Ophthalmol 2004;88:212–7.

    Article  CAS  Google Scholar 

  22. Ideta R, Tasaka F, Jang WD. Nano Lett 2005;5:2426–31.

    Article  CAS  Google Scholar 

  23. Tamaki Y. J Jpn Ophthalmol Soc 2007;111:232–69.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Yasuhiro Tamaki

Authors
  1. Yasuhiro Tamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuhiro Tamaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamaki, Y. Novel Drug Delivery System for Age-related Macular Degeneration Using Nanotechnology. Nanobiotechnol 3, 107–115 (2007). https://doi.org/10.1007/s12030-008-9001-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12030-008-9001-5

Keywords

Search

Navigation